Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?

Indian Heart Journal

Volumn 68, Issue 4, 2016, Pages 564-571

  John, Mathew ^a   Gopalakrishnan Unnikrishnan, Ambika ^b   Kalra, Sanjay ^c   Nair, Tiny ^d  

^a Providence Endocrine and Diabetes Specialty Centre   (India)

^b Chellaram Diabetes Institute   (India)

^c Bharti Hospital and BRIDE ^*  (India)

^d PRS Hospital   (India)

Author keywords

Anti diabetic drugs; Cardiovascular; Trials

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALEGLITAZAR; ALOGLIPTIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN GLARGINE; LINAGLIPTIN; LIXISENATIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; BODY WEIGHT GAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE MARKER; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; INCIDENCE; RISK FACTOR; TRENDS;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; GLOBAL HEALTH; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; RISK FACTORS;

EID: 84959449696     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ihj.2016.02.017     Document Type: Review

References (53)

1. Fox, C.S., Golden, S.H., Anderson, C., et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 38 (2015), 1777–1803.
2. Go, A.S., Mozaffarian, D., Roger, V.L., et al. Executive summary: heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 127 (2013), 143–152.
3. Gaede, P., Lund-Andersen, H., Parving, H.-H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008), 580–591.
4. Rao, A.D., Kuhadiya, N., Reynolds, K., et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31 (2008), 1672–1678.
5. Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
6. Salsburg, D.S., The UGDP study. JAMA 218 (1971), 1704–1705.
7. US Food and Drug Administration Guidance for industry: Diabetes mellitus — Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. [cited 2015 Nov 22]; Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf.
8. Bethel, M.A., Sourij, H., Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice. Curr Cardiol Rep 14 (2012), 59–69.
9. Hiatt, W.R., Kaul, S., Smith, R.J., The cardiovascular safety of diabetes drugs – insights from the rosiglitazone experience. N Engl J Med 369 (2013), 1285–1287.
10. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
11. White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
12. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
13. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
14. Holman, R.R., Sourij, H., Califf, R.M., Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet Lond Engl 383 (2014), 2008–2017.
15. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
16. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
17. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet Lond Engl 352 (1998), 837–853.
18. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
19. ADVANCE Collaborative Group, Patel, A., MacMahon, S., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
20. ®). Diabetes Vasc Dis Res 12 (2015), 164–174.
21. Vaccaro, O., Masulli, M., Bonora, E., et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care, 35, 2012, e82.
22. Marso, S.P., Poulter, N.R., Nissen, S.E., et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 166 (2013), 823–830 e5.
23. Neal, B., Perkovic, V., de Zeeuw, D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial. Am Heart J 166 (2013), 217–223 e11.
24. Sager, P.T., Seltzer, J., Turner, J.R., et al. Cardiovascular Safety Outcome Trials: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 169 (2015), 486–495.
25. UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet Lond Engl 352 (1998), 854–865.
26. Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
27. The Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) – Glucose lowering in those at risk of diabetes [Internet]. ISRCTN Registry. [cited 2015 Nov 22]; Available from: http://www.isrctn.com/ISRCTN34875079.
28. Dormandy, J.A., Charbonnel, B., Eckland, D.J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
29. Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 357 (2007), 28–38.
30. Aschner, P., Kipnes, M.S., Lunceford, J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006), 2632–2637.
31. DeFronzo, R., McMurray, J., EMPA-REG – the diuretic hypothesis. J. Diabetes Complicat., 2015, 10.1016/j.jdiacomp.2015.10.012.
32. Mahaffey, K.W., Harrington, R.A., Akkerhuis, M., et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2 (2001), 180–186.
33. Granger, C.B., Vogel, V., Cummings, S.R., et al. Do we need to adjudicate major clinical events?. Clin Trials 5 (2008), 56–60.
34. Frederich, R., Alexander, J.H., Fiedorek, F.T., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 122 (2010), 16–27.
35. Hirshberg, B., Raz, I., Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care 34 (2011), S101–S106.
36. Menon, V., Lincoff, A.M., Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus. Circulation 129 (2014), 2705–2713.
37. Lincoff, A.M., Tardif, J.C., Schwartz, G.G., et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 311 (2014), 1515–1525.
38. Henry, R.R., Buse, J.B., Wu, H., et al. Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. Diabetes Obes Metab 17 (2015), 560–565.
39. US Food and Drug Administration FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet]. [cited 2015 Nov 21]; Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.
40. Zhong, J., Goud, A., Rajagopalan, S., Glycemia lowering and risk for heart failure: recent evidence from studies of dipeptidyl peptidase inhibition. Circ Heart Fail 8 (2015), 819–825.
41. Cordoba, G., Schwartz, L., Woloshin, S., et al. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ, 341, 2010, c3920.
42. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 162 (2011), 818–825 e6.
43. Standl, E., Schnell, O., DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet 385 (2015), 2022–2024.
44. Jackson, N., Atar, D., Borentain, M., et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Eur Heart J, 2015 Jun 15. pii: ehv213. [Epub ahead of print].
45. Hirshberg, B., Katz, A., Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care 36 (2013), S253–S258.
46. Bloomgarden, Z., Grunberger, G., Cardiovascular safety trials: be careful what you wish for. J Diabetes 6 (2014), 1–3.
47. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus [Internet]. [cited 2015 Nov 22]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500115945.pdf.
48. Matthews, D.R., Cardiovascular trials and diabetes treatments: a regulatory maze. Diabetes Vasc Dis Res 9 (2012), 83–84.
49. Close, K., A Complicated Case of the Heart – FDA Meets on Heart Safety of Diabetes Drugs [Internet]. diaTribe 2015. 2015 [cited 2015 Nov 22] Available from: http://diatribe.org/complicated-case-heart-fda-meets-heart-safety-diabetes-drugs.
50. Bethel, M.A., Holman, R., Haffner, S.M., et al. Determining the most appropriate components for a composite clinical trial outcome. Am Heart J 156 (2008), 633–640.
51. Yayan, J., Emerging families of biomarkers for coronary artery disease: inflammatory mediators. Vasc Health Risk Manag 9 (2013), 435–456.
52. Barter, P.J., Caulfield, M., Eriksson, M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
53. Caveney, E.J., Cohen, O.J., Diabetes biomarkers. J Diabetes Sci Technol 5 (2011), 192–197.